iifl-logo

Sequent Scientific Ltd Quarterly Results

169.39
(-4.46%)
May 20, 2025|03:44:20 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Financials

Particulars (Rupees in Crores.)Mar-2025Dec-2024Sept-2024Jun-2024Mar-2024

Gross Sales

401.7

390.81

368.65

390.21

361.2

Excise Duty

0

0

0

0

0

Net Sales

401.7

390.81

368.65

390.21

361.2

Other Operating Income

0

0

0

0

0

Other Income

1.66

5.84

4.51

2.68

4

Total Income

403.36

396.65

373.16

392.89

365.2

Total Expenditure

355.8

356.62

333.87

348.26

333.64

PBIDT

47.56

40.03

39.29

44.63

31.56

Interest

15.13

14.95

14.29

16.38

12.44

PBDT

32.43

25.08

25

28.25

19.12

Depreciation

16.12

16.98

17.1

16.25

16.48

Minority Interest Before NP

0

0

0

0

0

Tax

12.93

8.83

7.97

11.16

3.45

Deferred Tax

-7

-7.21

-6.41

-8.22

-2.08

Reported Profit After Tax

10.38

6.48

6.34

9.06

1.27

Minority Interest After NP

1.06

3.04

3.73

2.55

2.19

Net Profit after Minority Interest

9.32

3.44

2.61

6.51

-0.92

Extra-ordinary Items

-0.07

0.03

0.04

0

-1.26

Adjusted Profit After Extra-ordinary item

9.39

3.41

2.57

6.51

0.34

EPS (Unit Curr.)

0.37

0.14

0.11

0.26

-0.04

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

0

0

0

0

0

Equity

50.06

50.06

49.92

49.9

49.89

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

11.83

10.24

10.65

11.43

8.73

PBDTM(%)

8.07

6.41

6.78

7.23

5.29

PATM(%)

2.58

1.65

1.71

2.32

0.35

Sequent Scien.: Related NEWS

Sequent Scientific jumps ~12% on ₹8,000 Crore merger with Viyash Life
27 Sep 2024|03:01 PM

Viyash manufactures active pharmaceutical ingredients (APIs) and drug formulations for the human health segment.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTOR

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.